"A unanimous panel of [U.S.] federal drug advisers on Monday concluded that Eli Lilly's experimental Alzheimer's drug donanemab benefits patients with early stages of the disease and that its benefits outweigh its risks."
@AxiosNews reports: https://flip.it/7_GWD0
#Alzheimers #Disease #EliLilly #Drugs #Pharmaceuticals #Medicine #Health #Aging
076萌SNS is a social network, courtesy of 076. It runs on GNU social, version 2.0.2-beta0, available under the GNU Affero General Public License.
All 076萌SNS content and data are available under the Creative Commons Attribution 3.0 license.